WINTON GROUP Ltd Makes New $2.73 Million Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

WINTON GROUP Ltd purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 95,266 shares of the company's stock, valued at approximately $2,726,000. WINTON GROUP Ltd owned about 0.20% of Pacira BioSciences as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. ICA Group Wealth Management LLC bought a new position in Pacira BioSciences in the fourth quarter valued at about $30,000. GAMMA Investing LLC lifted its holdings in Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock valued at $38,000 after acquiring an additional 932 shares during the period. Park Place Capital Corp bought a new position in Pacira BioSciences in the second quarter valued at about $46,000. Innealta Capital LLC bought a new position in Pacira BioSciences in the second quarter valued at about $50,000. Finally, nVerses Capital LLC lifted its holdings in Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock valued at $51,000 after acquiring an additional 1,600 shares during the period. Hedge funds and other institutional investors own 99.73% of the company's stock.

Insider Transactions at Pacira BioSciences

In related news, insider Jonathan Slonin sold 2,836 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total transaction of $80,117.00. Following the completion of the transaction, the insider now directly owns 95,557 shares of the company's stock, valued at $2,699,485.25. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Frank D. Lee purchased 8,264 shares of the company's stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average cost of $12.10 per share, with a total value of $99,994.40. Following the completion of the purchase, the chief executive officer now owns 107,784 shares in the company, valued at $1,304,186.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jonathan Slonin sold 2,836 shares of the company's stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $28.25, for a total value of $80,117.00. Following the sale, the insider now owns 95,557 shares in the company, valued at $2,699,485.25. The disclosure for this sale can be found here. Over the last 90 days, insiders acquired 11,176 shares of company stock valued at $136,240 and sold 4,281 shares valued at $105,494. Corporate insiders own 6.40% of the company's stock.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX traded up $0.38 during mid-day trading on Friday, reaching $13.11. The company's stock had a trading volume of 886,160 shares, compared to its average volume of 878,717. The firm has a market capitalization of $604.76 million, a PE ratio of 9.17 and a beta of 0.84. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.82 and a quick ratio of 5.70. The stock has a fifty day moving average of $17.16 and a two-hundred day moving average of $24.52. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $35.95.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.53 by $0.11. The firm had revenue of $178.02 million during the quarter, compared to analyst estimates of $173.31 million. Pacira BioSciences had a return on equity of 13.22% and a net margin of 9.21%. As a group, sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.24 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on PCRX shares. Royal Bank of Canada downgraded Pacira BioSciences from an "outperform" rating to a "sector perform" rating and lowered their target price for the company from $37.00 to $14.00 in a report on Monday, August 12th. HC Wainwright lowered their target price on Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating on the stock in a report on Monday, August 12th. Piper Sandler cut Pacira BioSciences from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $42.00 to $11.00 in a research report on Monday, August 12th. Raymond James cut Pacira BioSciences from an "outperform" rating to a "market perform" rating in a research report on Monday, August 12th. Finally, Barclays cut Pacira BioSciences from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $38.00 to $25.00 in a research report on Wednesday, July 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $24.78.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.